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EgyptAbstract Background: b-Globin mutations with Xmn1 site might be associated with elevated
HbF expression which may in turn ameliorate the severity of b-thalassemia phenotype.
Aim of the study: To investigate the frequency of 158 (C > T) XmnI polymorphism among
Egyptian Children and young adults with b-thalassemia, to examine the relationship between XmnI
polymorphism and b-thalassemia genotypes and phenotypes and to assess the possible relation of
XmnI polymorphism and response to hydroxyurea (Hu) therapy.
Patients and methods: Seventy-two b-thalassemia patients (37 females; M/F ratio 0.95) with a
mean age of 7.53 ± 6.99 were included. Laboratory investigations included Complete blood count
(CBC), Hb electrophoresis by high performance liquid chromatography (HPLC), b-thalassemia
mutation identification by the reverse dot blot hybridization technique (RDB) and detection of
XmnlGg polymorphism by RFLP.
Results: The frequency of positive heterozygote XmnI gene polymorphism was 8.3%. Eighty-
three percent of XmnIGc+/ patients were never transfused (p= 0.001) and had higher total hemo-
globin compared to XmnIGc/ (p= 0.01); while mean HbF was higher among XmnIGc+/
patients compared to the other group but the difference was marginally insignificant (p= 0.06).
b-Thalassemia mutation IVS II-1 showed relatively higher XmnI polymorphism frequency (50%)
and followed by its frequency among 10 undefined b-thalassemia mutations which was 20%. The
frequency of positive heterozygote XmnI gene polymorphism was 11.6% among the TI group vs.
3.5% among the TM group (p= 0.4). Among 20 cases who received HU; 5/14 responders vs. 1/
6 none responder had positive heterozygote XmnI gene polymorphism (p= 1.0).
Conclusions and recommendations: In conclusion, molecular determination of genetic markers in
childhood will help to identify phenotypes of our patients and to avoid over or under treatment
124 F. Said, A. Abdel-Salamstrategies. Further prospective studies concerning the genetic markers that could predict the
response to hemoglobin F inducers like hydroxyurea are highly recommended.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
b-Thalassemia syndromes are the most common form of
chronic hemolytic anemia due to impaired globin chain synthe-
sis [1]. The clinical presentation of b-thalassemia varies in
severity, ranging from severe transfusion-dependent anemia
to milder conditions [2]. One of the clinical challenges in the
management of b-thalassemia is to clearly identify the pheno-
type of patients as early as possible. This will help in avoiding
mismanagement with subsequent transformation of milder
syndromes to a severe one [3,4]. However, this early clear iden-
tification of the phenotype is not that simple; especially in
those who lie in the gray zone between the transfusion-depen-
dant thalassemia major and the non transfusion dependant
thalassemia intermedia.
A lot of progress has been made in understanding the
molecular basis of b-thalassemia and to help in predicting
phenotype from genotype [5–7]. It was found that the vari-
able phenotypes may occur from the nature of b-globin gene
mutations, a-thalassemia gene interaction or differences in
the amount of fetal hemoglobin (HbF) production [8]. In
the literature, there is a large body of evidence that increased
HbF production has an ameliorating effect in patients who
were mildly affected despite being homozygotes or compound
heterozygotes for b0 or b+ thalassemia [9–11]. This increase
of HbF production is genetically determined and partially
associated with b-haplotypes which show particular microsat-
ellite sequences and/or the XmnI polymorphism [12–14]. The
association of some b-globin mutations with Xmn1 site with
elevated HbF expression has been previously published
[9,15,13,16,17].
In this study we aimed to investigate the overall prevalence
of XmnI polymorphism among Egyptian Children and young
adults with b-thalassemia, to examine the relationship between
XmnI polymorphism and b-thalassemia genotypes and pheno-
types and to assess the possible relation of XmnI polymor-
phism and the response to hydroxyurea (Hu) therapy.
2. Patients and methods
This was an observational prospective study that included sev-
enty-two b-thalassemia patients; 37 (51.4%) females (male/
female ratio 0.95) with a mean age of 7.53 ± 6.99 (range:
0.6–29 years). Forty-three patients were diagnosed as thalasse-
mia intermedia (TI) based on conventional clinical (late pre-
sentation and/or transfusion independency) and hematologic
criteria [3]. All patients were regularly followed up at the Pedi-
atric Hematology Clinic of New Children Hospital, Faculty of
medicine, Cairo University. The study protocol was approved
by the Ethical Committee of Cairo University & the Ethical
Committee of National Research Center, Cairo, Egypt,
according to the Institutional Committee for the Protection
of Human Subjects and adopted by the 18th World Medical
Assembly, Helsinki, Finland.All patients underwent medical history clinical examina-
tion. Fourteen patients were treated with hydroxyurea (HU)
in a dose ranging from 10 to 20 mg/kg/day orally once a day
for at least 3 months.
Laboratory investigations included a complete blood count
using (Ceii-Dyn 3700 hematology analyzer), Hb electrophore-
sis by high performance liquid chromatography (HPLC) using
the VARIANT II b-thalassemia Short Program, Bio-Rad Lab-
oratories [18]. b-Thalassemia mutation identification of sam-
ples was performed by the reverse dot blot hybridization
technique (RDB). For RDB, a panel of primers and probes
(n = 22) using the beta globin strip assay was used (b-Globin
Strip Assay MED kit, VIENNA LAB) [19].
Detection of GcXmnI polymorphism of C to T base pair
substitution at the 158 position in the promoter region of
the Gc-globin gene (158 (C > T) XmnI polymorphism):
Blood samples were collected from patients into EDTA vacu-
tainers for genomic DNA analysis by polymerase chain reac-
tion–restriction fragment-length polymorphism (PCR–
RFLP). DNA was extracted using the QI Amp DNA Mini
Kit; Blood Mini Kit (Catalog No: 51104). The primer set used
for DNA amplification was the 50-AAC TGT TGC TTT ATA
GGA TTT T-30 and 50-AGG AGC TTA TTG ATA ACT
CAG AC-30 [20]. PCR was performed using a Perkin Elmer
Thermal Cycler Gen Amp 9700 (Applied Biosystems, UK).
A total volume of 25 ll PCR reaction contained 12.5 ll of
ready-to-use PCR Master Mix, 5, 5 ll of nuclease-free water,
1 ll (20 pmol) of primer F, 1 ll (20 pmol) of primer R and
5 ll of genomic extracted DNA.
The cycling reaction was performed under the following
conditions: Denaturation at 95 C for 10 min, 30 cycles of
denaturation at 94 C for 1 min, primer annealing at 55 C
for 1 min, extension at 72 C for 1 min and final extension at
72 C for 10 min. The PCR products were digested with the
XMN 1 restriction enzyme. Digestion products were electro-
phoresed on a 3% agarose gel. Amplification with the primers
produced a 650 bp fragment in the wild genotype, the hetero-
zygous genotype gives 2 bands at 400 bp and 250 bp [20].
2.1. Statistical analysis
SigmaStat program; version 3.5 (Systat Software, Inc., USA)
was used for Data management and analysis. Numerical data
were presented as mean ± SD or median and interquartile
range (IQR). Comparisons between numerical variables
between two groups were done by Student’s t test for parametric
data orMann–WhitneyRankSum test for non-parametric data.
Comparing of categorical variables was done by Fisher exact
test. P < 0.05 was considered significant for all statistical tests.
3. Results
Seventy-two patients were included; their baseline demo-
graphic and clinical characteristics are illustrated in Table 1.
Table 1 Demographic and clinical data of the studied cases (n= 72).
Variables All patients (N= 72)
Mean ± SD (range) Median (IQR)
Age at 1st transfusion (mo) (n = 57) 34.25 ± 56.40 (2.0–324.0) 14 (7–36)
Age at diagnosis (mo) 26.82 ± 22.35 (2–96) 24 (8.25–40.5)
Total hemoglobin (g/dl) 7.26 ± 1.45 (4.5–10.7) 7.35 (6.15–8.45)
Hemoglobin F (%) 43.46 ± 26.23 (0–100) 41.00 (23.0–59.0)
TR* (times/year) (n= 57) 12.38 ±4.52 (4–24) 12 (10.5–12)
* TR: transfusion rate.
Figure 1 PCR Polymorphisms of the Gc-globin gene (158
(C > T) XMN1 polymorphism in b-thalassemia patients: Lane
1:UX174 DNA/BsuRI (HaeIII) Marker. Lane 2,4–6: 650 bp
fragment from patients with XmnI (/) genotype. Lane 3 and
7:650 bp, 450 bp and 200 bp fragment from a patient heterozygous
for the XmnI (+/) genotype.
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polymorphism among the studied patients was 8.3%. Eighty-
three percent of XmnIGc+/ patients were never transfused
(p= 0.001) and had significantly higher total hemoglobin
compared to XmnIGc/ (p= 0.01); meanwhile mean HbF
was higher among XmnIGc+/ patients compared to the otherTable 2 Comparison of XmnIGc/ and XmnIGc+/ patients.




Age at diagnosis (mo)
Mean ± SD (range) 25.694 ± 22.045
Median (IQR) 20.0 (8.0–36.0)
Hb (g/dl)
Mean ± SD (range) 7.123 ± 1.420
Median (IQR) 7.1 (6.1–7.9)
Hb F (%)
Mean ± SD (range) 41.502 ± 26.042




* Statistically significant.group but the difference was marginally insignificant
(p= 0.06) (Fig. 1 and Table 2).
3.1. XmnIGc polymorphism and b-thalassemia mutations
Among the 72 patients, 26 different genotypes were identified.
There were 37 homozygous patients, while the rest were com-
pound heterozygous. Twenty-five of the 37 (67.6%) homozy-
gous patients were the products of consanguineous
marriages. The most frequent mutation among homozygous
patients was IVS-I-6 followed by IVS-I-110. The most frequent
compound heterozygous state was IVS 1–110 (G > A)/IVS 1.6
T > C. b-Thalassemia mutation IVS II-1 showed relatively
higher XmnI polymorphism frequency (50%) regarding other
b-thalassemia mutations observed in our patients and it was
followed by the frequency of positive heterozygote XmnI gene
polymorphism among 10 undefined b-thalassemia mutations
in 72 patients which was 20% (Table 3).
3.2. XmnIGc polymorphism and b-thalassemia phenotype and
response to hydroxyurea (HU) therapy
The frequency of positive heterozygote XmnI gene polymor-
phism was 11.6% among the TI group vs. 3.5% among the
TM group (p = 0.4). Among 20 cases who received HU; 5/XmnIGc+/ (n= 6) p-value
1 (16.7%) 0.391
5 (83.3%)
40.80 ± 23.774 0.161
42.0(28.5–54.0)
8.683 ± 1.025 0.011*
8.9 (7.5–9.6)




Table 4 XmnIGc polymorphism of the studied patients in relation to clinical phenotype and response to hydroxycarbamide (Hu).
Phenotype p-value HU response p-value
TI (n= 43) TM (n= 29) Yes (n= 14) No (n= 6)
XmnIGc/ 38 (88.37%) 28 (96.55%) 0.391 10 (71.4%) 5 (83.3%) 1.000
XmnIGc/+ 5 (11.63%) 1 (3.45%) 4 (28.6%) 1 (16.6%)
Table 3 Genotype study of patients with positive XmnI polymorphism (n= 6).
Genotype b/b No of cases Clinical syndrome
IVS 1–110 (G > A)/IVS 1.6 (T > C) +/+ 1 TI
IVS 1.1 (G > A)/IVS 1.6 (T > C) 0/+ 1 TM
IVS 2.1(G > A)/not characterized 0/? 1 TI
IVS 2.1(G > A)/IVS 2.745(C > G) 0/+ 1 TI
Not characterized / 2 TI
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gote XmnI gene polymorphism (1.0) (Table 4).
4. Discussion
Positive XmnI gene polymorphism was reported to be one of
the main phenotype modifying factors of b-thalassemia
[6,13,14,20,22,23]. In this study we aimed to investigate the
overall prevalence of XmnI polymorphism among Egyptian
Children and young adults with b-thalassemia, to examine
the relationship between XmnI polymorphism and b-thalasse-
mia genotypes and phenotypes and to assess the possible rela-
tion of XmnI polymorphism and the response to hydroxyurea
(Hu) therapy.
We found that the overall frequency of positive heterozy-
gote XmnI gene polymorphism was 8.3% in our b-thalassemia
patients. Our data showed significant differences in transfusion
dependency as most of XmnI positive patients were transfu-
sion independent, and total hemoglobin level in XmnIGc+/
patients, and also HbF was higher among XmnIGc+/
patients compared to the other group but the difference was
marginally insignificant (p= 0.06). This was in line with ear-
lier studies that confirmed that the presence of the Xmnl poly-
morphism might contribute to overproduction of HbF,
causing mild features of b-thalassemia [16,24,25]. In addition,
patients with Xmnl polymorphism were usually transfusion
independent or had an older age at first transfusions [26].
To our knowledge, few previous studies compared the fre-
quency of positive heterozygote XmnI gene polymorphism in
thalassemia major and intermedia and found no statistically
significant difference [23,27], and two previous studies carried
out to assess it among Egyptian b-thalassemia patients and
reported a frequency 9% in b-thalassemia intermedia patients
[16] and 4% in b-thalassemia major patients [17]. Our data
were in line with the previous reports; the frequency of positive
heterozygote XmnI gene polymorphism was 11.6 % among the
TI group vs. 3.5% among the TM group (p = 0.4).
Also, we observed that 2/4 chromosomes with IVS II-
1(G > A), 2/45 chromosomes with IVS I-6 (T > C) mutation
and 2 out of 10 chromosomes with non characterized mutations
were positive for the XmnI [+] polymorphism. This means that
b-thalassemia mutation IVS II-1 showed the highest XmnIpolymorphism frequency (50%) when compared to other b-
thalassemia mutations observed in our patients. Previous stud-
ies reported that several b-globin gene mutations including
codon 44 (C), IVS I-5 (G > C), IVS II-1 (G > A)  87
(C > G) and FSC 8 (AA) were positive for the XmnI [+]
polymorphism in different countries [6,7,13,21–23,28].
Our data showed that XmnI polymorphism had no impact
on the response to hydroxyurea. This was in concordance with
previous studies that reported no correlation between the pres-
ences of XmnI polymorphism and response to HU therapy in
b-thalassemia patients [7,29].
However, other researchers reported that the response to
HU was significantly correlated with the presence of XmnI
polymorphism [28,30,31].
Our study is one of few studies that compared the frequency
of globin gene promoter XmnI polymorphism in thalassemia
major and thalassemia intermedia and is the first to report
the frequency of XmnI polymorphism in Egyptian b-thalasse-
mia patients in relation to b-thalassemia chromosomes.
In conclusion, molecular determination of genetic markers
in early childhood will help to identify phenotypes of our
patients and to avoid over or under treatment strategies. Fur-
ther prospective studies concerning the genetic markers that
could predict the response to hemoglobin F inducers like
hydroxyurea (HU) are highly recommended.
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